Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

HMX toxicokinetic, metabolism and distribution assessment is based on the data from toxicokinetics studies following single oral and intravenous administrations (Cameron, 1986), acute oral and dermal studies (Cuthbert et al., 1985) , in vitro skin absorption study (Reifenrath, 2002), and subacute and subchronic repeat dose studies (Everett et al., 1985; Everett and Maddock., 1985) . These studies suggest that HMX is poorly absorbed via the oral and dermal routes. Most of an orally administered dose of HMX is excreted in the faeces as unchanged HMX within 96h. The small amount of HMX that is absorbed in the body may be temporarily found, particularly in the plasma, lungs, liver, heart, and kidneys. However, the levels of HMX in these tissues do not remain elevated for very long. Data indicate that HMX is readily metabolised to polar intermediates; however, these metabolites have not been identified. Most of an absorbed dose of HMX is excreted in the urine within 4 days.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential
Absorption rate - oral (%):
5
Absorption rate - dermal (%):
4

Additional information